Publications by authors named "Omar Khaznadar"
Article Synopsis
- Approximately one billion people are affected by metabolic-associated fatty liver disease (MAFLD), a chronic liver condition linked to metabolic issues like obesity and type 2 diabetes, which can lead to severe liver complications with minimal treatment options.
- The successful treatment for MAFLD requires a drug that reduces liver fat, inflammation, and fibrosis, with a focus on improving liver tissue health, but currently, only a few drugs like Saroglitazar have been approved in limited regions.
- Recent advancements show that research efforts are ramping up, with several promising drug candidates nearing approval, including Rezdiffra™, which received accelerated approval in the U.S. for treating MAFLD this year.
In the current modern era of unhealthy lifestyles, non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and has become a serious global health problem. To date, there is no approved pharmacotherapy for the treatment of NAFLD, and necessary lifestyle changes such as weight loss, diet, and exercise are usually not sufficient to manage this disease. Patients with type 2 diabetes mellitus (T2DM) have a significantly higher risk of developing NAFLD and vice versa.
View Article and Find Full Text PDF